Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients

Journal of Hypertension

Volumn 23, Issue 12, 2005, Pages 2313-2318

  Jordan, Jens ^a   Engeli, Stefan ^a   Boschmann, Michael ^a   Weidinger, Gottfried ^c   Luft, Friedrich C ^a   Sharma, Arya M ^b   Kreuzberg, Ursula ^c  

^a FRANZ VOLHARD CLINIC   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c Winicker Norimed   (Germany)

Author keywords

AT1 receptor blockers; Beta blockers; Obesity associated hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; GERMANY; GLUCOSE METABOLISM; HEART HEMODYNAMICS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 27944491573     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000188734.98463.82     Document Type: Article

References (20)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-1529.
2. Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002; 26:48-57.
3. Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: The Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001; 9:188-195.
4. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141:81-85.
5. Rocchini AP. Obesity hypertension. Am J Hypertens 2002; 15(2 Pt 2):50S-52S.
6. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362.
7. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304:930-933.
8. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538-542.
9. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17:1125-1133.
10. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17:961-969.
11. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19:470-475.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
13. Schmieder RE, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment. BMJ 1993; 307:537-540.
14. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14(7 Pt 1):694-698.
15. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20:965-973.
16. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15:2727-2729.
17. Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, et al. Tissue-specific response to interstitial angiotensin II in humans. Hypertension 2003; 41:37-41.
18. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
19. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37:250-254.
20. Boschmann M, Engeli S, Adams F, Gorzelniak K, Franke G, Klaua S, et al. Adipose tissue metabolism and CD11b expression on monocytes in obese hypertensives. Hypertension 2005; 46:130-136.